These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

300 related items for PubMed ID: 1505913

  • 21. Effects of ursodeoxycholic acid (UDCA) on serum liver damage indices in patients with chronic active hepatitis. A double-blind controlled study.
    Rolandi E, Franceschini R, Cataldi A, Cicchetti V, Carati L, Barreca T.
    Eur J Clin Pharmacol; 1991; 40(5):473-6. PubMed ID: 1679391
    [Abstract] [Full Text] [Related]

  • 22. A prospective, randomized-controlled pilot study of ursodeoxycholic acid combined with mycophenolate mofetil in the treatment of primary sclerosing cholangitis.
    Sterling RK, Salvatori JJ, Luketic VA, Sanyal AJ, Fulcher AS, Stravitz RT, Contos MJ, Mills AS, Shiffman ML.
    Aliment Pharmacol Ther; 2004 Nov 01; 20(9):943-9. PubMed ID: 15521841
    [Abstract] [Full Text] [Related]

  • 23. Metabolomic profiling of 17 bile acids in serum from patients with primary biliary cirrhosis and primary sclerosing cholangitis: a pilot study.
    Trottier J, Białek A, Caron P, Straka RJ, Heathcote J, Milkiewicz P, Barbier O.
    Dig Liver Dis; 2012 Apr 01; 44(4):303-10. PubMed ID: 22169272
    [Abstract] [Full Text] [Related]

  • 24. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression.
    Sinakos E, Marschall HU, Kowdley KV, Befeler A, Keach J, Lindor K.
    Hepatology; 2010 Jul 01; 52(1):197-203. PubMed ID: 20564380
    [Abstract] [Full Text] [Related]

  • 25. Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease.
    Beuers U, Spengler U, Zwiebel FM, Pauletzki J, Fischer S, Paumgartner G.
    Hepatology; 1992 Apr 01; 15(4):603-8. PubMed ID: 1551637
    [Abstract] [Full Text] [Related]

  • 26. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
    Harnois DM, Angulo P, Jorgensen RA, Larusso NF, Lindor KD.
    Am J Gastroenterol; 2001 May 01; 96(5):1558-62. PubMed ID: 11374699
    [Abstract] [Full Text] [Related]

  • 27. Seladelpar (MBX-8025), a selective PPAR-δ agonist, in patients with primary biliary cholangitis with an inadequate response to ursodeoxycholic acid: a double-blind, randomised, placebo-controlled, phase 2, proof-of-concept study.
    Jones D, Boudes PF, Swain MG, Bowlus CL, Galambos MR, Bacon BR, Doerffel Y, Gitlin N, Gordon SC, Odin JA, Sheridan D, Wörns MA, Clark V, Corless L, Hartmann H, Jonas ME, Kremer AE, Mells GF, Buggisch P, Freilich BL, Levy C, Vierling JM, Bernstein DE, Hartleb M, Janczewska E, Rochling F, Shah H, Shiffman ML, Smith JH, Choi YJ, Steinberg A, Varga M, Chera H, Martin R, McWherter CA, Hirschfield GM.
    Lancet Gastroenterol Hepatol; 2017 Oct 01; 2(10):716-726. PubMed ID: 28818518
    [Abstract] [Full Text] [Related]

  • 28. No beneficial effects of transdermal nicotine in patients with primary sclerosing cholangitis: results of a randomized double-blind placebo-controlled cross-over study.
    Vleggaar FP, van Buuren HR, van Berge Henegouwen GP, Hop WC, van Erpecum KJ.
    Eur J Gastroenterol Hepatol; 2001 Feb 01; 13(2):171-5. PubMed ID: 11246617
    [Abstract] [Full Text] [Related]

  • 29. A placebo-controlled trial of primary biliary cirrhosis treatment with colchicine and ursodeoxycholic acid.
    Vuoristo M, Färkkilä M, Karvonen AL, Leino R, Lehtola J, Mäkinen J, Mattila J, Friman C, Seppälä K, Tuominen J.
    Gastroenterology; 1995 May 01; 108(5):1470-8. PubMed ID: 7729640
    [Abstract] [Full Text] [Related]

  • 30. Improvement of biliary enzyme levels and itching as a result of long-term administration of ursodeoxycholic acid in primary biliary cirrhosis.
    Matsuzaki Y, Tanaka N, Osuga T, Aikawa T, Shoda J, Doi M, Nakano M.
    Am J Gastroenterol; 1990 Jan 01; 85(1):15-23. PubMed ID: 1967512
    [Abstract] [Full Text] [Related]

  • 31. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy.
    Poupon RE, Chrétien Y, Poupon R, Paumgartner G.
    Hepatology; 1993 Apr 01; 17(4):599-604. PubMed ID: 8477964
    [Abstract] [Full Text] [Related]

  • 32. Effects of ursodeoxycholic acid and taurine on serum liver enzymes and bile acids in chronic hepatitis.
    Podda M, Ghezzi C, Battezzati PM, Crosignani A, Zuin M, Roda A.
    Gastroenterology; 1990 Apr 01; 98(4):1044-50. PubMed ID: 1968871
    [Abstract] [Full Text] [Related]

  • 33. Ursodeoxycholic acid for the treatment of primary biliary cirrhosis. Interim analysis of a double-blind multicentre randomized trial. The UDCA-PBC Study Group.
    Poupon RE, Eschwège E, Poupon R.
    J Hepatol; 1990 Jul 01; 11(1):16-21. PubMed ID: 1975819
    [Abstract] [Full Text] [Related]

  • 34. Effect of ursodeoxycholic acid on bile acid metabolism in primary biliary cirrhosis.
    Batta AK, Salen G, Arora R, Shefer S, Tint GS, Abroon J, Eskreis D, Katz S.
    Hepatology; 1989 Oct 01; 10(4):414-9. PubMed ID: 2777202
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and safety of curcumin in primary sclerosing cholangitis: an open label pilot study.
    Eaton JE, Nelson KM, Gossard AA, Carey EJ, Tabibian JH, Lindor KD, LaRusso NF.
    Scand J Gastroenterol; 2019 May 01; 54(5):633-639. PubMed ID: 31131678
    [Abstract] [Full Text] [Related]

  • 36. Ursodeoxycholic acid therapy in treatment of primary sclerosing cholangitis.
    Stiehl A.
    Scand J Gastroenterol Suppl; 1994 May 01; 204():59-61. PubMed ID: 7824879
    [Abstract] [Full Text] [Related]

  • 37. Association between reduced levels of alkaline phosphatase and survival times of patients with primary sclerosing cholangitis.
    Lindström L, Hultcrantz R, Boberg KM, Friis-Liby I, Bergquist A.
    Clin Gastroenterol Hepatol; 2013 Jul 01; 11(7):841-6. PubMed ID: 23353641
    [Abstract] [Full Text] [Related]

  • 38. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
    Fickert P, Wagner M, Marschall HU, Fuchsbichler A, Zollner G, Tsybrovskyy O, Zatloukal K, Liu J, Waalkes MP, Cover C, Denk H, Hofmann AF, Jaeschke H, Trauner M.
    Gastroenterology; 2006 Feb 01; 130(2):465-81. PubMed ID: 16472600
    [Abstract] [Full Text] [Related]

  • 39. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM, Schrumpf E.
    Tidsskr Nor Laegeforen; 1997 Sep 30; 117(23):3370-3. PubMed ID: 9411890
    [Abstract] [Full Text] [Related]

  • 40. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
    van Milligen de Wit AW, Kuiper H, Camoglio L, van Bracht J, Jones EA, Tytgat GN, van Deventer SJ.
    Eur J Gastroenterol Hepatol; 1999 Feb 30; 11(2):129-36. PubMed ID: 10102223
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.